GW Pharmaceuticals price target raised to $65 from $22 at Lazard Capital Lazard Capital raised its price target significantly for GW Pharmaceuticals to $65 citing the company's orphan program for epilepsy. The firm calls GW one of the most compelling opportunities its ever seen and keeps a Buy rating on the stock.
News For GWPH From The Last 14 Days
Check below for free stories on GWPH the last two weeks.
On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: Altisource Residential (RESI) initiated with a Buy at Deutsche Bank... Cedar Fair (FUN) initiated with an Outperform at FBR Capital... Chimerix (CMRX) initiated with an Overweight at Piper Jaffray... GW Pharmaceuticals (GWPH) initiated with an Overweight at Piper Jaffray... Insmed (INSM) initiated with an Overweight at Piper Jaffray... Merchant Bancshares (MBVT) initiated with a Buy at Sterne Agee... Nektar (NKTR) initiated with an Overweight at Piper Jaffray... Oi S.A. (OIBR) initiated with an Outperform at Bernstein... Qunar (QUNR) initiated with a Hold at Deutsche Bank... Repros Therapeutics (RPRX) initiated with an Overweight at Piper Jaffray... Ruckus Wireless (RKUS) initiated with a Buy at Stifel... SeaWorld (SEAS) initiated with a Market Perform at FBR Capital... Six Flags (SIX) initiated with a Market Perform at FBR Capital... Twitter (TWTR) initiated with a Buy at MKM Partners... Surgical Care Affiliates (SCAI) initiated with a Buy at SunTrust.
GW Pharmaceuticals announces Sativex regulatory approval in Switzerland GW Pharmaceuticals announced that it has received regulatory approval for its prescription medicine Sativex in Switzerland. A full marketing authorization has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis patients who have not responded adequately to other anti-spasticity medications. Launch timing is dependent on completion of pricing and reimbursement procedures. Sativex will be commercialized in Switzerland by GW's European partner, Almirall S.A.